As per MRFR analysis, the US Bone Biopsy Market Size was estimated at 190.4 (USD Million) in 2023.The US Bone Biopsy Market Industry is expected to grow from 201.6 (USD Million) in 2024 to 411.69 (USD Million) by 2035. The US Bone Biopsy Market CAGR (growth rate) is expected to be around 6.706% during the forecast period (2025 - 2035).
The US Bone Biopsy Market is experiencing several important trends driven by advancements in medical technology, rising demand for minimally invasive procedures, and an increasing prevalence of bone-related diseases such as cancer and osteoporosis. One key market driver is the growing geriatric population in the United States, which is more susceptible to these conditions and, consequently, requires more diagnostic assessments. Technological innovations, including the development of specialized biopsy needles and imaging techniques, are enhancing the efficiency and accuracy of procedures, thus fostering higher adoption rates among healthcare providers.
Expanding access to these procedures in outpatient settings presents notable opportunities within this market. As part of value-based care initiatives and improving patient outcomes, healthcare systems in the US seek more affordable and less invasive treatment options. This not only improves recovery times but also decreases hospital stays, benefiting both patients and providers. More recently, the integration of digital solutions and telemedicine into biopsy procedures is on the rise. This includes remote imaging review and virtual consultations, which enhance patient experience and diagnostic precision.
Furthermore, educational initiatives aimed at training healthcare professionals on the latest biopsy techniques and technologies are enhancing the overall standard of care in the US. As these trends evolve, the US Bone Biopsy Market is poised for continued growth while addressing the changing needs of the population and healthcare system.
Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review
The US Bone Biopsy Market Industry is experiencing growth driven primarily by the increasing incidence of bone-related diseases such as cancer and osteoporosis. According to the Centers for Disease Control and Prevention (CDC), approximately 54 million adults in the United States are affected by low bone mass, putting them at increased risk for osteoporosis-related fractures. Furthermore, the American Cancer Society reports that in 2022, an estimated 1.9 million new cancer cases were diagnosed, with bone cancers such as multiple myeloma expected to see a rise.
This surge in the prevalence of diseases requiring bone biopsies forms a substantial driver for market expansion as healthcare providers seek to confirm diagnoses effectively and quickly, illustrating the intertwined relationship between disease incidence and the demand for diagnostic procedures in the US Bone Biopsy Market Industry.
Technological advancements are driving the growth of the US Bone Biopsy Market Industry by improving the efficiency and accuracy of biopsy procedures. Innovations such as minimally invasive techniques, advanced imaging technologies, and the use of automated biopsy systems are evolving how procedures are conducted. Reports from the Food and Drug Administration (FDA) indicate that several new device approvals have emerged over the last few years, such as higher precision and lower complication rate devices.
This evolution in technology allows for more accurate diagnosis and treatment, contributing to the overall growth of the market. Moreover, established organizations like Medtronic and Boston Scientific are actively investing in Research and Development (R&D) to enhance these technologies, thus bolstering the industry's capacity for advanced diagnostics.
There is a growing demand for personalized medicine, which is driving the US Bone Biopsy Market Industry forward. The National Institutes of Health (NIH) illustrates that personalized medicine allows healthcare providers to tailor treatments based on individual patients’ genetic profiles and disease characteristics. This customization is leading to more effective treatments and improved patient outcomes. The prevalence of bone biopsies has significantly increased as these procedures facilitate genomic and molecular testing of tumor samples, which is crucial for personalized therapy approaches.
With more healthcare institutions adopting precision medicine practices, the demand for bone biopsies is expected to rise substantially. Additionally, organizations like the American Association for Cancer Research are advocating for the integration of personalized approaches in clinical practice, reinforcing the market's growth potential.
Growing public awareness and acceptance of diagnostic procedures, including bone biopsy, are substantially propelling the US Bone Biopsy Market Industry. Increased advocacy and educational initiatives by organizations such as the American Society of Clinical Oncology have heightened awareness regarding the importance of early diagnosis in combating cancer and bone diseases. The National Cancer Institute highlights that early detection can significantly increase the survival rates for various cancers, including bone-related malignancies.
As a result, patients are more informed and proactive in seeking these diagnostic procedures. This shift towards patient-initiated demand is expected to increase the volume of procedures performed, thereby driving market growth over the next few years.
The US Bone Biopsy Market is significantly shaped by its Type segmentation, which primarily encompasses Needle Biopsy and Open Biopsy. Needle Biopsy has emerged as a preferred choice among healthcare professionals due to its minimally invasive nature, which greatly reduces patient recovery time and associated complications compared to more invasive procedures. This method is pivotal in obtaining bone marrow samples, aiding in the diagnosis of various bone conditions, including cancers and hematologic disorders. As technological advancements continue to enhance the precision and efficacy of Needle Biopsy techniques, their application is expected to rise further, reflecting the current preferences in clinical settings.
In contrast, Open Biopsy represents a more traditional approach, often utilized when deeper tissue samples are required or when Needle Biopsy is deemed insufficient. This procedure, although more invasive, plays a critical role in specific clinical scenarios, particularly where comprehensive tissue assessment is essential. While it may involve longer recovery periods and higher risks, Open Biopsy remains a vital option in the biopsy arsenal, thus ensuring that healthcare providers can choose the most suitable method based on patient needs and specific diagnostic requirements.
Noteworthy trends in the US Bone Biopsy Market indicate a growing inclination towards less invasive procedures that promise shorter downtime, underscoring the importance of Needle Biopsy. Moreover, as awareness surrounding the effectiveness of early diagnosis and timely intervention escalates, both Needle Biopsy and Open Biopsy continue to gain traction. The interplay between these techniques and advancements in imaging technologies enhances the overall diagnostic landscape of bone-related conditions in the US. As the population ages and the incidence of bone diseases increases, the demand for efficient and reliable biopsy techniques is expected to grow, further propelling these segment dynamics.
The evolving nature of the US Bone Biopsy Market exemplifies the broader trends in surgical methods, with a clear shift towards procedures that prioritize patient comfort and safety while maintaining diagnostic accuracy. Market growth will be increasingly influenced by innovations within each segment, addressing the specific needs of clinicians and patients alike, thereby solidifying their relevance in routine clinical practice.
Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review
The Guided segment of the US Bone Biopsy Market is gaining traction due to advancements in imaging technologies and their growing applications in diagnosing bone-related ailments. This segment includes MRI-Guided and CT-Guided biopsies, both of which are critical for obtaining precise tissue samples with minimal discomfort and injury. MRI-Guided techniques are notable for their ability to visualize soft tissue structures and tumors in real-time, thereby improving the accuracy of diagnostics. Meanwhile, CT-Guided biopsies are widely utilized due to their effectiveness in targeting hard-to-reach lesions, further driving the demand for these imaging methods in clinical settings.
The integration of these guided approaches allows for enhanced procedural precision, which is vital in oncology and infectious disease cases. With the increasing prevalence of bone disorders and the demand for minimally invasive procedures in the United States, the Guided segment is positioned for significant growth. Overall, the US Bone Biopsy Market continues to evolve, with innovation and technology shaping its future trajectory.
The US Bone Biopsy Market is experiencing notable growth, particularly among various End User segments, including Hospitals and Clinics, Surgical Centers, and Others. Within this market, Hospitals and Clinics play a pivotal role as they are primary locations for diagnostic and interventional procedures related to bone conditions, leveraging advanced technology and skilled healthcare professionals. Surgical Centers are increasingly becoming significant as they offer specialized services and cater to outpatient needs, providing efficient and timely care.
The Others segment includes various specialized facilities that contribute to patient care in unique ways. The demand for bone biopsy procedures in the US is driven by an increasing prevalence of bone-related diseases, advancements in imaging technologies, and the growing emphasis on early diagnosis and treatment. Additionally, the aging population in the US presents an opportunity for market growth as older individuals are more prone to conditions requiring biopsy procedures. Overall, the segmentation within the US Bone Biopsy Market highlights the diverse landscape of healthcare facilities that are essential in managing patient needs and driving market dynamics.
The US Bone Biopsy Market showcases a dynamic landscape characterized by a range of prominent players and emerging companies striving for a competitive edge. Key factors driving competition include technological advancements, product innovation, and the growing prevalence of bone-related disorders, which elevate the demand for effective diagnostic techniques. As companies focus on enhancing the quality of their offerings, customer preferences are shifting towards minimally invasive procedures and increased diagnostic accuracy.
The competitive insights reveal a market where leading firms are leveraging both strategic partnerships and mergers to bolster their position, while new entrants challenge established players with innovative solutions and cost-effective options. The collaboration between various stakeholders, including healthcare providers, technology firms, and research institutions, is vital in shaping market dynamics and driving growth.
Biopsy Sciences has positioned itself as a significant player in the US Bone Biopsy Market through its commitment to developing refined biopsy devices that cater to the specific needs of healthcare professionals and their patients. The company's strength lies in its robust product portfolio, comprising advanced biopsy needles and access devices designed for targeted bone sampling.
Biopsy Sciences prioritizes user experience, ensuring that their products not only meet clinical requirements but also enhance procedural efficiency. With a strong focus on research and development, the company stays ahead of the curve by integrating feedback from healthcare practitioners and adapting its offerings to meet evolving standards. The firm's reputation for reliability and quality has solidified its presence in the market, enabling it to attract a loyal customer base and expand geographically within the United States.
Cure Medical distinguishes itself in the US Bone Biopsy Market with a focus on high-quality medical devices and innovative solutions designed for optimal patient care. Known for its commitment to accessibility and performance, Cure Medical offers a range of products that include specialized biopsy kits and related instruments, which facilitate accurate and effective bone sampling.
The company has strived to build a strong market presence through strategic collaborations, enhancing its distribution networks, and ensuring that its products reach a broad audience, including hospitals and outpatient surgical centers. Cure Medical has demonstrated growth through strategic mergers and partnerships, allowing it to reinforce its core competencies while expanding its technological capabilities. The emphasis on producing safe and effective medical devices, combined with an adaptive business strategy, positions the company favorably within the competitive landscape of the US Bone Biopsy Market.
The US Bone Biopsy Market has witnessed notable developments in recent months. In August 2023, Biopsy Sciences launched a new minimally invasive bone biopsy device that enhances precision and reduces patient recovery time, addressing a growing trend towards less invasive procedures. Cure Medical and ConMed are collaborating on a Research and Development initiative to create innovative biopsy tools that improve diagnostic capabilities within the oncology sector.Â
Additionally, Merit Medical reported a significant increase in sales for their bone biopsy kits, driven by the rise in osteoporotic fractures among the aging population in the US, which is projected to influence market growth positively in the coming years. In terms of mergers and acquisitions, Stryker acquired the assets of a smaller competitor specializing in advanced biopsy technologies in July 2023, consolidating its position in the market.Â
Moreover, Hologic's expansion of its product line in September 2023 has bolstered its presence within the segmented market. The overall market valuation for companies like Medtronic and Boston Scientific is on the rise as they invest in innovative technologies and expand their service offerings, contributing to an increasingly competitive landscape in the US Bone Biopsy Market.
| Report Attribute/Metric | Details |
| Market Size 2023 | 190.4 (USD Million) |
| Market Size 2024 | 201.6 (USD Million) |
| Market Size 2035 | 411.69 (USD Million) |
| Compound Annual Growth Rate (CAGR) | 6.706% (2025 - 2035) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Biopsy Sciences, Cure Medical, ConMed, Cook Medical, Neusoft Medical Systems, Boston Scientific, Smith & Nephew, BD, Merit Medical, Stryker, Argon Medical Devices, Medtronic, Hologic, Terumo Corporation, Erlangen Medical |
| Segments Covered | Type, Guided, End User |
| Key Market Opportunities | Technological advancements in biopsy tools, increasing cancer prevalence demands, growing minimally invasive procedures, rising geriatric population, enhanced diagnostics and imaging techniques |
| Key Market Dynamics | Increasing prevalence of bone disorders, advancements in biopsy technologies, rising geriatric population, growing demand for minimally invasive procedures, increasing awareness, and early diagnosis |
| Countries Covered | US |
Frequently Asked Questions (FAQ) :
The US Bone Biopsy Market is expected to be valued at 201.6 million USD in 2024.
The market is projected to have a compound annual growth rate (CAGR) of 6.706% from 2025 to 2035.
By 2035, the US Bone Biopsy Market is expected to reach approximately 411.69 million USD.
Needle biopsy is expected to dominate the market with a value of 120.8 million USD in 2024.
The needle biopsy segment is expected to increase to 247.1 million USD by 2035.
The open biopsy segment is projected to be valued at 80.8 million USD in 2024.
By 2035, the open biopsy segment is anticipated to grow to 164.59 million USD.
Some key players include Biopsy Sciences, Cure Medical, ConMed, and Boston Scientific, among others.
Technological advancements and the increasing prevalence of bone diseases are key growth drivers.
Regulatory hurdles and the high cost of biopsy procedures may pose challenges to market growth.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
